Researchers observed that when TMZ was administered close to the daily peak in Bmal1 expression, both primary mesenchymal murine GBM astrocytes and primary human GBM were most sensitive to TMZ (Slat et al., 2017). The gene discussed is BMAL1; the disease is glioblastoma.